Kuros Biosciences AG (CSBTF)
USD 34.0
(4.94%)
USD 34.0
(4.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.69 Million CHF | 60.77% |
| 2022 | -22.15 Million CHF | 16.33% |
| 2021 | -26.47 Million CHF | -1.65% |
| 2020 | -26.04 Million CHF | -41.46% |
| 2019 | -18.41 Million CHF | -0.44% |
| 2018 | -18.33 Million CHF | -9.96% |
| 2017 | -16.67 Million CHF | -34.8% |
| 2016 | -12.36 Million CHF | -872.1% |
| 2015 | 1.6 Million CHF | -92.24% |
| 2014 | 20.65 Million CHF | 240.72% |
| 2013 | -14.67 Million CHF | -0.08% |
| 2012 | -14.66 Million CHF | -231.27% |
| 2011 | 11.17 Million CHF | 112.54% |
| 2010 | 5.25 Million CHF | -82.98% |
| 2009 | 30.89 Million CHF | 50.23% |
| 2008 | 20.56 Million CHF | 33.9% |
| 2007 | 15.35 Million CHF | 293.69% |
| 2006 | -7.92 Million CHF | 30.87% |
| 2005 | -11.46 Million CHF | 45.47% |
| 2004 | -21.03 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -8.7 Million CHF | 13.76% |
| 2024 Q1 | -14.27 Million CHF | -64.29% |
| 2023 Q1 | -14.57 Million CHF | 34.22% |
| 2023 Q2 | -13.99 Million CHF | 3.97% |
| 2023 FY | -8.69 Million CHF | 60.77% |
| 2023 Q3 | -12.64 Million CHF | 9.65% |
| 2023 Q4 | -8.69 Million CHF | 31.27% |
| 2022 Q4 | -22.15 Million CHF | 1.84% |
| 2022 FY | -22.15 Million CHF | 16.33% |
| 2022 Q1 | -19.92 Million CHF | 24.75% |
| 2022 Q2 | -19.61 Million CHF | 1.55% |
| 2022 Q3 | -22.56 Million CHF | -15.04% |
| 2021 Q2 | -24.81 Million CHF | 1.23% |
| 2021 FY | -26.47 Million CHF | -1.65% |
| 2021 Q3 | -26.79 Million CHF | -7.97% |
| 2021 Q4 | -26.47 Million CHF | 1.18% |
| 2021 Q1 | -25.12 Million CHF | 3.54% |
| 2020 Q1 | -12.93 Million CHF | 29.75% |
| 2020 Q4 | -26.04 Million CHF | 1.06% |
| 2020 Q3 | -26.32 Million CHF | -107.9% |
| 2020 FY | -26.04 Million CHF | -41.46% |
| 2020 Q2 | -12.66 Million CHF | 2.1% |
| 2019 Q3 | -18.66 Million CHF | -93.53% |
| 2019 Q1 | -9.89 Million CHF | 46.06% |
| 2019 FY | -18.41 Million CHF | -0.44% |
| 2019 Q4 | -18.41 Million CHF | 1.32% |
| 2019 Q2 | -9.64 Million CHF | 2.51% |
| 2018 FY | -18.33 Million CHF | -9.96% |
| 2018 Q4 | -18.33 Million CHF | 0.0% |
| 2018 Q3 | -18.33 Million CHF | -89.99% |
| 2018 Q2 | -9.65 Million CHF | 0.0% |
| 2018 Q1 | -9.65 Million CHF | 42.12% |
| 2017 Q3 | -16.67 Million CHF | 22.15% |
| 2017 Q2 | -21.41 Million CHF | 0.0% |
| 2017 Q1 | -21.41 Million CHF | -73.15% |
| 2017 FY | -16.67 Million CHF | -34.8% |
| 2017 Q4 | -16.67 Million CHF | -0.0% |
| 2016 Q4 | -12.36 Million CHF | 0.0% |
| 2016 Q2 | -17.44 Million CHF | 0.0% |
| 2016 FY | -12.36 Million CHF | -872.1% |
| 2016 Q1 | -17.44 Million CHF | -1189.01% |
| 2016 Q3 | -12.36 Million CHF | 29.1% |
| 2015 Q2 | -2.16 Million CHF | 0.0% |
| 2015 Q4 | 1.6 Million CHF | 113.08% |
| 2015 FY | 1.6 Million CHF | -92.24% |
| 2015 Q3 | -12.24 Million CHF | -466.11% |
| 2014 FY | 20.65 Million CHF | 240.72% |
| 2014 Q4 | 20.65 Million CHF | 0.0% |
| 2014 Q2 | 12.94 Million CHF | 0.0% |
| 2013 Q4 | -14.67 Million CHF | -506.85% |
| 2013 Q3 | 3.6 Million CHF | 296.84% |
| 2013 Q2 | -1.83 Million CHF | 79.51% |
| 2013 FY | -14.67 Million CHF | -0.08% |
| 2013 Q1 | -8.94 Million CHF | 39.01% |
| 2012 Q4 | -14.66 Million CHF | 31.06% |
| 2012 FY | -14.66 Million CHF | -231.27% |
| 2012 Q3 | -21.27 Million CHF | 11.92% |
| 2012 Q2 | -24.15 Million CHF | -1760.0% |
| 2012 Q1 | 1.45 Million CHF | -86.98% |
| 2011 Q4 | 11.17 Million CHF | 31.66% |
| 2011 Q1 | 6.1 Million CHF | 16.05% |
| 2011 Q2 | 10.86 Million CHF | 78.15% |
| 2011 FY | 11.17 Million CHF | 112.54% |
| 2011 Q3 | 8.48 Million CHF | -21.92% |
| 2010 Q3 | 20.15 Million CHF | 24.02% |
| 2010 Q1 | 33.91 Million CHF | 9.77% |
| 2010 FY | 5.25 Million CHF | -82.98% |
| 2010 Q4 | 5.25 Million CHF | -73.91% |
| 2010 Q2 | 16.24 Million CHF | -52.09% |
| 2009 FY | 30.89 Million CHF | 50.23% |
| 2009 Q4 | 30.89 Million CHF | 0.0% |
| 2008 FY | 20.56 Million CHF | 33.9% |
| 2007 FY | 15.35 Million CHF | 293.69% |
| 2006 FY | -7.92 Million CHF | 30.87% |
| 2005 FY | -11.46 Million CHF | 45.47% |
| 2004 FY | -21.03 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1191.063% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 815.882% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 962.346% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 120.307% |
| GB Sciences, Inc. | 1.74 Million USD | 597.334% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 1.696% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -93660.048% |
| Skye Bioscience, Inc. | -5.72 Million USD | -51.886% |
| Zenith Capital Corp. | 10.06 Thousand USD | 86447.377% |
| Agentix Corp. | 37.63 Thousand USD | 23192.663% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 253.85% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1321.532% |
| ContraFect Corporation | -6.02 Million USD | -44.208% |
| CSL Limited | 10.52 Billion USD | 100.083% |
| CytoDyn Inc. | 20.26 Million USD | 142.888% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2515.835% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1496.289% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 120.007% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -42481.341% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1037.245% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1468.144% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -37.838% |
| SQZ Biotechnologies Company | -36.23 Million USD | 76.02% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1110.182% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 155.129% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 487.56% |
| Mesoblast Limited | 55.85 Million USD | 115.557% |
| Marizyme, Inc. | 18.56 Million USD | 146.798% |
| Genus plc | 190.6 Million USD | 104.559% |
| Pharming Group N.V. | 109.8 Million USD | 107.914% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1377.941% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 852.102% |
| IMV Inc. | 7.67 Million USD | 213.291% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 257.946% |
| MultiCell Technologies, Inc. | 90.04 USD | 9651366.104% |
| ONE Bio Corp. | 9.04 Million USD | 196.128% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 167.125% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 128.441% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 534.632% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 167.856% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 6315.845% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 43840.877% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -4628.274% |
| Enzolytics Inc. | 981.65 Thousand USD | 985.239% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.572% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 81.515% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 222.897% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.181% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 311.024% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2262.504% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 464.203% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 5382.386% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -47339.677% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 488.67% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 6554.296% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1083.959% |
| Helix BioMedix, Inc. | -2.57 Million USD | -238.128% |
| EV Biologics, Inc. | 1.36 Million USD | 735.247% |
| Q BioMed Inc. | 4.06 Million USD | 314.039% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 142.859% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 114.353% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 294.32% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 494.645% |
| HST Global, Inc. | 96.79 Thousand USD | 9077.922% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -663258.779% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 4314.008% |
| Halberd Corporation | 144.72 Thousand USD | 6104.657% |
| Resverlogix Corp. | 6.45 Million USD | 234.708% |
| Cell Source, Inc. | 9.23 Million USD | 194.129% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 420.828% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -47.208% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 4435.635% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 498.905% |
| Kadimastem Ltd | -253.1 Thousand USD | -3333.398% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 6490.223% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 4417.927% |
| LadRx Corporation | -2.03 Million USD | -326.719% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1468.144% |
| Affymax, Inc. | -5.59 Million USD | -55.262% |
| Itoco Inc. | 228.3 Thousand USD | 3906.312% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 275.308% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1894.594% |
| International Stem Cell Corporation | 2.59 Million USD | 435.521% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 557.63% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1343022.102% |
| Qrons Inc. | 351.42 Thousand USD | 2572.775% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 212.769% |
| SYBLEU INC | 473.71 Thousand USD | 1934.44% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -3381.292% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2949.18% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 294.973% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 14023.381% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 498.459% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 353.058% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 201.602% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1224.763% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -595.2% |
| Neutra Corp. | 52.18 Thousand USD | 16751.657% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -249.136% |
| PureTech Health plc | -167.19 Million USD | 94.803% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -3448.271% |
| IXICO plc | -4.44 Million USD | -95.519% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 165.739% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 115.843% |
| CSL Limited | 10.52 Billion USD | 100.083% |
| Cellectis S.A. | -43.81 Million USD | 80.168% |